LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (TA939)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 December 2023
Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC